Profiling of lipid mediators in atherosclerotic carotid plaques from type 2 diabetic and non-diabetic patients.
Fiche publication
Date publication
août 2022
Journal
Prostaglandins, leukotrienes, and essential fatty acids
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Jean-Michel, Dr PAIS DE BARROS Jean-Paul, Pr MASSON David
Tous les auteurs :
Ménégaut L, Laubriet A, Crespy V, Nguyen M, Petit JM, Tarris G, Pilot T, Varin A, Choubley H, Bergas V, de Barros JP, Thomas C, Steinmetz E, Masson D
Lien Pubmed
Résumé
Diabetes is associated with an accelerated development of atherosclerosis. Specific mechanisms related to diabetes and hyperglycemia may play a role in this process. In particular, alterations of arachidonic acid (AA) metabolism have been reported. Our main goal was to investigate for differences in the concentration of LTB4 and RvD1 as well as selected cyclooxygenase-derived mediators in carotid plaques from diabetic and non-diabetic patients. We also aimed to analyze the relationship between omega 6 and omega 3 Poly-Unsaturated Fatty acids (PUFAs) content in the plaques and the concentrations of these lipid mediators.
Mots clés
Arachidonic acid, Atherosclerosis, DHA, Diabetes, EPA, Leukotriene, Resolvin
Référence
Prostaglandins Leukot Essent Fatty Acids. 2022 08 4;184:102477